Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral infections and cancer VLP vaccines - TechnoVax

Next Previous
Drug Profile

Research programme: viral infections and cancer VLP vaccines - TechnoVax

Alternative Names: Cancer vaccine - TechnoVax; Dengue vaccine - TechnoVax; HIV vaccine - TechnoVax; Inhaled powder influenza VLP vaccine - TechnoVax; Inhaled powder RSV VLP vaccine - TechnoVax; Pandemic influenza vaccine - TechnoVax; Respiratory syncytial virus (RSV) VLP vaccine - TechnoVax; Seasonal tetravalent influenza VLP vaccine - TechnoVax; Universal influenza vaccine - TechnoVax; Virus-like particle (VLP) vaccines - TechnoVax; Zika virus vaccine - TechnoVax; ZIKA VLP vaccine - TechnoVax

Latest Information Update: 28 Jun 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TechnoVax
  • Developer City University of New York; TechnoVax
  • Class AIDS vaccines; Cancer vaccines; Dengue vaccines; Influenza A vaccines; Influenza virus vaccines; Virus-like particle vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Dengue; HIV infections; Influenza virus infections; Parainfluenza virus infections; Respiratory syncytial virus infections; Zika virus infection

Most Recent Events

  • 28 Jun 2021 No recent reports of development identified for preclinical development in Zika-virus-infection in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Dengue in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top